Pluri Inc. is a biotechnology company that operates a proprietary 3D cell expansion platform enabling industrial-scale manufacturing of living cells for therapeutic, food, and agricultural applications. The company develops allogeneic cell therapy products derived from placental tissue for conditions including muscle recovery, blood disorders, and cancer; offers contract manufacturing services for cell-based therapies through its PluriCDMO division; and holds equity stakes in ventures producing cultivated meat and cell-cultured agricultural products. Pluri generates revenue through government research grants and contracts, cell therapy manufacturing service fees, equity investments and revenue sharing arrangements with partner ventures, collaboration payments, and royalties on licensed therapies and manufacturing processes.